Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C17H26N6O4 |
| Molecular Weight | 378.4261 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
N[C@@H](CCCCN1C=CC=C2N=C(NCCC[C@H](N)C(O)=O)N=C12)C(O)=O
InChI
InChIKey=AYEKKSTZQYEZPU-RYUDHWBXSA-N
InChI=1S/C17H26N6O4/c18-11(15(24)25)5-1-2-9-23-10-4-7-13-14(23)22-17(21-13)20-8-3-6-12(19)16(26)27/h4,7,10-12H,1-3,5-6,8-9,18-19H2,(H,20,21)(H,24,25)(H,26,27)/t11-,12-/m0/s1
| Molecular Formula | C17H26N6O4 |
| Molecular Weight | 378.4261 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Advanced glycation end product ligands for the receptor for advanced glycation end products: biochemical characterization and formation kinetics. | 2004-01-01 |
|
| High levels of urinary pentosidine, an advanced glycation end product, in children with acute exacerbation of atopic dermatitis: relationship with oxidative stress. | 2003-12 |
|
| Application of monoclonal antibody libraries for the measurement of glycation adducts. | 2003-12 |
|
| Removal of advanced glycation end products in clinical renal failure by peritoneal dialysis and haemodialysis. | 2003-12 |
|
| Methylglyoxal-derived hydroimidazolone advanced glycation end-products of human lens proteins. | 2003-12 |
|
| Glycoxidation and inflammation in chronic haemodialysis patients. | 2003-12 |
|
| Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. | 2003-11-01 |
|
| Paradoxical impact of antioxidants on post-Amadori glycoxidation: Counterintuitive increase in the yields of pentosidine and Nepsilon-carboxymethyllysine using a novel multifunctional pyridoxamine derivative. | 2003-10-03 |
|
| [Age-related post-translational modification of proteins in human tissue and its use determination of age in forensic medicine. Review]. | 2003-10 |
|
| The protective effect of aminoguanidine on erectile function in streptozotocin diabetic rats. | 2003-10 |
|
| Effect of the peritoneal dialysis prescription on pentosidine in children. | 2003-10 |
|
| Advanced glycation end-products pentosidine and N epsilon-carboxymethyllysine are elevated in serum of patients with osteoporosis. | 2003-10 |
|
| Glyoxal and methylglyoxal levels in diabetic patients: quantitative determination by a new GC/MS method. | 2003-09 |
|
| The involvement of advanced glycation endproducts (AGEs) in renal injury of diabetic glomerulosclerosis: association with phenotypic change in renal cells and infiltration of immune cells. | 2003-09 |
|
| Association between blood indoxyl sulfate and carbonyl stress marker in hemodialysis patients. | 2003-09 |
|
| Gelatin degradation at elevated temperature. | 2003-09 |
|
| Prevention of retinal capillary basement membrane thickening in diabetic dogs by a non-steroidal anti-inflammatory drug. | 2003-09 |
|
| Formation of advanced glycosylation end products and oxidative stress in young patients with type 1 diabetes. | 2003-09 |
|
| Increased concentration of pentosidine, an advanced glycation end product, and interleukin-6 in the vitreous of patients with proliferative diabetic retinopathy. | 2003-08 |
|
| Modification of elastin by pentosidine is associated with the calcification of aortic media in patients with end-stage renal disease. | 2003-08 |
|
| Effect of smoking on risk factors for cardiovascular disease in patients with diabetes mellitus and renal insufficiency. | 2003-07-31 |
|
| The changes in crosslink contents in tissues after formalin fixation. | 2003-07-01 |
|
| Vascular risk factors and markers of endothelial function as determinants of inflammatory markers in type 1 diabetes: the EURODIAB Prospective Complications Study. | 2003-07 |
|
| The effect of caloric restriction on glycation and glycoxidation in skin collagen of nonhuman primates. | 2003-06 |
|
| Plasma pentosidine is associated with inflammation and malnutrition in end-stage renal disease patients starting on dialysis therapy. | 2003-06 |
|
| The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats. | 2003-06 |
|
| Increased levels of advanced glycation end products in human cataractous lenses. | 2003-05 |
|
| Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. | 2003-05 |
|
| A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients. | 2003-05 |
|
| Improvement in quality of diabetes control and concentrations of AGE-products in patients with type 1 and insulin-treated type 2 diabetes mellitus studied over a period of 10 years (JEVIN). | 2003-03-05 |
|
| Are advanced glycation end products cardiovascular risk factors in patients with CRF? | 2003-03 |
|
| Increased urinary levels of pentosidine, pyrraline and acrolein adduct in type 2 diabetes. | 2003-02 |
|
| Advanced glycation end-products in anterior chamber aqueous of cataractous patients. | 2003-02 |
|
| Serum levels of total homocysteine, homocysteine metabolites and of advanced glycation end-products (AGEs) in patients after renal transplantation. | 2003-02 |
|
| Advanced glycation endproducts and osteoarthritis. | 2003-02 |
|
| Cellular uptake of beta2M and AGE-beta2M in synovial fibroblasts and macrophages. | 2003-01 |
|
| Advanced glycation end-product (AGE)-damaged IgG and IgM autoantibodies to IgG-AGE in patients with early synovitis. | 2003 |
|
| Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes. | 2002-12-31 |
|
| Pentosidine and N(epsilon)-(carboxymethyl)-lysine in Alzheimer's disease and vascular dementia. | 2002-12-25 |
|
| Induction of advanced glycation end products and alterations of the tensile properties of articular cartilage. | 2002-12 |
|
| Levels of mature cross-links and advanced glycation end product cross-links in human vitreous. | 2002-11-30 |
|
| Time-resolved and steady-state fluorescence spectroscopic studies of the human lens with comparison to argpyrimidine, pentosidine and 3-OH-kynurenine. | 2002-11 |
|
| Glycation by ascorbic acid causes loss of activity of ribulose-1,5-bisphosphate carboxylase/oxygenase and its increased susceptibility to proteases. | 2002-11 |
|
| Are advanced glycation end-product-modified proteins of pathogenetic importance in fibromyalgia? | 2002-10 |
|
| Creatine plays a direct role as a protein modifier in the formation of a novel advanced glycation end product. | 2002-10 |
|
| Low parathyroid hormone and pentosidine in hemodialysis patients. | 2002-10 |
|
| Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. | 2002-10 |
|
| Relationship between glycoxidation and cytokines in the vitreous of eyes with diabetic retinopathy. | 2002-09-13 |
|
| Accumulation of imidazolone, pentosidine and N(epsilon)-(carboxymethyl)lysine in hippocampal CA4 pyramidal neurons of aged human brain. | 2002-09 |
|
| Serum pentosidine as an indicator of Alzheimer's disease. | 2002-04 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 23:30:13 GMT 2025
by
admin
on
Mon Mar 31 23:30:13 GMT 2025
|
| Record UNII |
BJ4I2X2CQJ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID60154417
Created by
admin on Mon Mar 31 23:30:13 GMT 2025 , Edited by admin on Mon Mar 31 23:30:13 GMT 2025
|
PRIMARY | |||
|
119593
Created by
admin on Mon Mar 31 23:30:13 GMT 2025 , Edited by admin on Mon Mar 31 23:30:13 GMT 2025
|
PRIMARY | |||
|
PENTOSIDINE
Created by
admin on Mon Mar 31 23:30:13 GMT 2025 , Edited by admin on Mon Mar 31 23:30:13 GMT 2025
|
PRIMARY | |||
|
124505-87-9
Created by
admin on Mon Mar 31 23:30:13 GMT 2025 , Edited by admin on Mon Mar 31 23:30:13 GMT 2025
|
PRIMARY | |||
|
BJ4I2X2CQJ
Created by
admin on Mon Mar 31 23:30:13 GMT 2025 , Edited by admin on Mon Mar 31 23:30:13 GMT 2025
|
PRIMARY |